Background: Pediatric hematopoietic cell transplant (HCT) recipients often fail to have robust responses to influenza (flu) vaccine. We conducted a blinded phase II trial comparing high-dose (HD) trivalent inactivated vaccine (TIV) vs. standard dose (SD) quadrivalent inactivated vaccine (QIV).
Background: Current season vaccine effectiveness (VE) and influenza risk may vary in persons based on vaccination history. United States Influenza Vaccine Effectiveness (US Flu VE) Network studies have explored prior vaccination effects using a single referent group of patients unvaccinated in both the prior and current seasons. We investigated vaccine benefit among those with and without prior season vaccination.
Methods: Our analysis included data from the US Flu VE Network among patients aged ≥9 years old with acute respiratory illness during 6 influenza seasons, 2012-2013 through 2017-2018. We determined current and prior season vaccination status from documented immunizations. Current season VE against laboratory confirmed influenza was estimated using multivariate logistic regression with an interaction term for prior and current season vaccination. Models were adjusted for age, calendar time, high-risk status, and site.
Results: Of 31,819 patients included in the analysis over 6 seasons, 9188 were influenza positive by RT-PCR. Percent flu positivity was greatest among those unvaccinated (34%), followed by those vaccinated in the prior season only (29%), those vaccinated in both seasons (25%), and those vaccinated in the current season only (23%). Among patients with prior season vaccination, current season VE against any influenza was 14% (95% CL: 5, 22) and against A(H3N2), A(H1N1)pdm09, and B was 10% (95% CL: 3, 17), 36% (95%CL: 25, 46), and 40% (95% CL: 33, 46), respectively. Among patients unvaccinated in the prior season, VE was 42% (95% CL: 37, 46) against any influenza in the current season and was 31% (95%CL: 22, 39), 57% (95% CL: 47, 65), and 55% (95% CL: 48, 61) against A(H3N2), A(H1N1)pdm09, and B, respectively. We observed significant interaction of prior season vaccination on current season VE in 4 of 6 seasons (P < 0.20).
Conclusion: Current season vaccination was overall protective regardless of vaccination history. Among those vaccinated in the prior season, current season vaccination may provide some benefit in addition to residual protection from previous vaccination.
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Interventions to Improve Influenza Vaccination Coverage in Children with Medical Comorbidities: A Meta-Analysis
Results: 35 articles met inclusion criteria; 14 cross-sectional, 12 randomized trials, and 9 cohort studies, 25 articles had sufficient data for pooled analysis. Of the included interventions, 17 were based within primary care or community-based settings, 17 were based in hospitals or tertiary clinics, and 1 intervention was conducted across both primary and tertiary settings. Interventions overall increased influenza vaccination likelihood by 33% (RR = 1.33: 95% CI 1.31, 1.35). Interventions targeting providers' influenza vaccine knowledge increased vaccine coverage (RR = 1.42: 95% CI 1.36, 1.49) greater than those targeting parental knowledge (RR = 1.23: 95% CI 1.21, 1.26). Conversely, vaccination reminders targeting parents increased vaccine coverage (RR = 1.53: 95% CI 1.49, 1.58) greater than reminders targeting providers (RR = 1.23: 95% CI 1.20, 1.27). Interventions targeting hospitals, clinics or ward processes had the weakest impact on coverage (RR = 1.15: 95% CI 1.13, 1.17).
Conclusion: Interventions targeting parents, providers, and places individually have all shown to improve influenza vaccination in children with medical comorbidities. However, specifically targeting providers' vaccine knowledge and parental reminders appear to have the greatest impact on vaccine uptake.
Disclosures. All authors: No reported disclosures. vaccine administered as first dose between 12-15 months, and second dose between 4-6 years, administered either separately or as a combination MMRV vaccine. Vaccine coverage alone does not provide information on the timeliness of vaccine receipt, a critical step in ensuring optimal protection, thus, we sought to evaluate overall series completion rates and identify factors related to under-vaccination.
A Cohort
Methods: A cohort of children born between 2006 and 2010, with continuous enrollment from birth to age 7 in the MarketScan® Commercial Claims and Encounters Database was studied. The administration of first and second doses of MMR-and V-containing vaccines was evaluated. Administration timeliness was categorized as recommended, acceptably early (prior to age 4 for the second dose), late (after the recommended time period), invalid, or missing at least one vaccine. A logistic regression analysis evaluated factors associated with under-vaccination.
Results: Among the 104,999 children included, 55.9% were vaccinated within the recommended time periods for both first and second doses, with timeliness higher for the second dose (80.1%) than the first dose (63.5%). By age 4, 20.1% of children were missing the first dose of either MMR or V (or both) and by age 7, 26.6% of children were missing at least one dose, with 9.4% missing all required vaccines. Factors associated with missed or delayed vaccination included geographic region, vaccination by a provider other than a pediatrician, and, for the second dose, having missed or delayed the first dose. Having additional children in the family was associated with a higher likelihood of missed or delayed vaccination for the first dose, but with a lower likelihood of missed or delayed vaccination for the second dose.
Conclusion: About one in four children were missing at least one dose of MMR or V by age 7, indicating vaccine coverage is below Healthy People 2020 95% target. Additionally, delays in administration of the first dose indicate a potential for the development of cohorts of susceptible children large enough to sustain outbreaks. Strategies for addressing timeliness of vaccine receipt should incorporate factors associated with under-vaccination.
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